Alpha-0261

Alpha-0261 is an investigational, orally bioavailable small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R). Developed by AlphaMol Science, a biotechnology company that leverages artificial intelligence and computational biology for drug discovery, Alpha-0261 is being evaluated for the treatment of metabolic disorders, specifically obesity and type 2 diabetes mellitus. By activating the GLP-1 receptor, the drug mimics the physiological actions of the incretin hormone GLP-1, which include stimulating glucose-dependent insulin secretion, inhibiting glucagon release, slowing gastric emptying, and increasing satiety. As a non-peptide small molecule, Alpha-0261 is designed to offer a more convenient oral dosing regimen compared to the injectable peptide-based GLP-1 receptor agonists currently used in clinical practice.